RESUMO
Rheumatoid arthritis (RA), an autoimmune inflammatory disorder is currently incurable. Methotrexate and Teriflunomide are routinely prescribed drugs but their uses are limited due to severe hepatotoxicity. Hyaluronic acid (HYA) is a targeting ligand for CD44 receptors overexpressed on inflamed macrophages. The present investigation aimed at design and fabrication of HYA coated hydroxyapatite nanoparticles (HA-NPs) loaded with Methotrexate (MTX) and Teriflunomide (TEF) (HAMT-NPs) to form HYA-HAMT-NPs for the treatment of RA. HYA-HAMT-NPs showed the nanoscale size of 274.9 ± 64 nm along with a zeta potential value of -26.80 ± 6.08 mV. FTIR spectra of HYA and HYA-HAMT-NPs proved the coating of HYA on HYA-HAMT-NPs. HYA-HAMT-NPs showed less cell viability compared to drugs on RAW 264.7 macrophage cells. A biodistribution study by gamma scintigraphy imaging further strengthened the results by revealing significantly higher (p<0.05) percentage radioactivity (76.76%) of HYA-HAMT-NPs in the synovial region. The results obtained by pharmacodynamic studies ensured the better efficacy of HYA-HAMT-NPs in preventing disease progression and promoting articular regeneration. Under hepatotoxicity evaluation, liver histopathology and liver enzyme assay revealed ~29% hepatotoxicity was reduced by HYA-HAMT-NPs when compared to conventional FOLITRAX-10 and AUBAGIO oral treatments. Overall, the results suggest that HYA-HAMT-NP is a promising delivery system to avoid drug-induced hepatotoxicity in RA.
Assuntos
Antirreumáticos/administração & dosagem , Artrite Experimental/tratamento farmacológico , Artrite Reumatoide/tratamento farmacológico , Crotonatos/administração & dosagem , Portadores de Fármacos/administração & dosagem , Durapatita/química , Ácido Hialurônico/química , Metotrexato/administração & dosagem , Nanopartículas/administração & dosagem , Toluidinas/administração & dosagem , Animais , Antirreumáticos/farmacocinética , Antirreumáticos/uso terapêutico , Antirreumáticos/toxicidade , Artrite Experimental/patologia , Crotonatos/farmacocinética , Crotonatos/uso terapêutico , Crotonatos/toxicidade , Citocinas/sangue , Portadores de Fármacos/farmacocinética , Portadores de Fármacos/toxicidade , Avaliação Pré-Clínica de Medicamentos , Liberação Controlada de Fármacos , Hidroxibutiratos , Fígado/efeitos dos fármacos , Fígado/enzimologia , Fígado/patologia , Metotrexato/farmacocinética , Metotrexato/uso terapêutico , Metotrexato/toxicidade , Camundongos , Nanopartículas/toxicidade , Nitrilas , Células RAW 264.7 , Ratos , Ratos Wistar , Espectroscopia de Infravermelho com Transformada de Fourier , Distribuição Tecidual , Toluidinas/farmacocinética , Toluidinas/uso terapêutico , Toluidinas/toxicidadeRESUMO
This research aims to coat Teriflunomide (TEF) loaded conventional nanoliposomes (CON-TEF-LIPO) with Chondroitin sulphate (CS) to produce CS-TEF-LIPO for the effective treatment of Rheumatoid arthritis (RA). Both CON-TEF-LIPO and CS-TEF-LIPO were produced, characterized and evaluated for their active targeting potential towards CD44 receptors. Cell cytotoxicity, cell viability and intracellular uptake study on differentiated U937 and MG-63 cells demonstrated the active targeting of CS-TEF-LIPO towards CD44 receptors. Furthermore, in vivo pharmacodynamic, biochemical, radiological and histopathological studies performed in adjuvant induced arthritic (AIA) rat model showed a significant (P < 0.05) reduction in inflammation in arthritic rat paw in CS-TEF-LIPO group compared to TEF and CON-TEF-LIPO groups. Moreover, liver toxicity study revealed that CS-TEF-LIPO showed no signs of toxicity and biodistribution study revealed the accumulation of CS-TEF-LIPO in synovial region of arthritic rat. Taken together, results suggest that CS-TEF-LIPO could provide a new insight for an effective treatment of RA.
Assuntos
Artrite Experimental/tratamento farmacológico , Artrite Reumatoide/tratamento farmacológico , Sulfatos de Condroitina/química , Crotonatos/farmacologia , Glioma/tratamento farmacológico , Lipossomos/administração & dosagem , Nanopartículas/administração & dosagem , Toluidinas/farmacologia , Animais , Artrite Experimental/patologia , Artrite Reumatoide/patologia , Crotonatos/farmacocinética , Glioma/patologia , Humanos , Hidroxibutiratos , Lipossomos/química , Masculino , Nanopartículas/química , Nitrilas , Ratos , Ratos Wistar , Distribuição Tecidual , Toluidinas/farmacocinética , Células Tumorais CultivadasRESUMO
The aim of this investigation is the management of rheumatoid arthritis (RA) by developing methotrexate-loaded calcium phosphate nanoparticles (MTX-CAP-NP) and to evaluate pharmacokinetic and pharmacodynamic behavior in adjuvant induced arthritis model. The nanoparticles were synthesized by wet precipitation method and optimized by Box-Behnken experimental design. MTX-CAP-NPs were characterized by TEM, FTIR, DSC and XRD studies. The particle size, zeta potential and entrapment efficiency of the optimized nanoparticles were found to be 204.90 ± 64 nm, -11.58 ± 4.80 mV, and 88.33 ± 3.74%, respectively. TEM, FTIR, DSC and XRD studies revealed that the developed nanoparticles were nearly spherical in shape and the crystalline structure of CAP-NP was not changed after MTX loading. The pharmacokinetic studies revealed that MTX-CAP-NP enhanced bioavailability of MTX by 2.6-fold when compared to marketed formulation (FOLITRAX-10). Under pharmacodynamic evaluation, arthritic assessment, radiography and histopathology studies revealed that CAP has ability to regenerate cartilage and bone therefore, together with MTX, MTX-CAP-NPs have shown significant reduction in disease progression. The overall work demonstrated that the developed nanodelivery system was well tolerated and more effective than the marketed formulation.
Assuntos
Fosfatos de Cálcio/química , Metotrexato/química , Metotrexato/farmacocinética , Nanopartículas/química , Animais , Artrite Experimental/tratamento farmacológico , Artrite Reumatoide/tratamento farmacológico , Disponibilidade Biológica , Portadores de Fármacos/química , Feminino , Metotrexato/farmacologia , Tamanho da Partícula , Ratos , Ratos WistarRESUMO
PURPOSE: The present investigation was aimed at developing Teriflunomide (TEF) and Methotrexate (MTX) loaded hydroxyapatite nanoparticles and increasing tolerability towards combination therapy against rheumatoid arthritis by reducing hepatotoxicity. METHODS: Drug-loaded HAp-NPs were synthesized by wet-chemical precipitation method and optimized by Box-Behnken experimental design. The developed NPs were subjected to in vitro and in vivo characterization. In-vivo pharmacodynamics and biochemical studies were performed on adjuvant- induced arthritis model treated with different formulations; MTX-TEF-SOL, TEF-HAp-NP, MTX-HAp-NP, TEF-MTX-HAp-NP, FOLITRAX-10 and AUBAGIO. RESULTS: The size of the optimized formulations, TEF-HAp-NP and MTX-HAp-NP, was found to be 224.3 ± 83.80 nm and 268.3 ± 73.86 nm with drug loading 53.11 ± 0.84% and 67.04 ± 1.12% respectively. In vitro release of TEF from TEF-HAp-NP (70.41 ± 1.22%) and MTX from MTX-HAp-NP (82.43 ± 1.31%) up to 24 h revealed sustained release pattern. Results of the arthritic assessment study showed a significant (P < 0.05) reduction in ankle diameter (61.30 ± 7.42) and arthritis score (2.35 ± 0.24) with a marked restoration of ankle joint micro-architecture in TEF-MTX-HAp-NP treated group. During Hepatotoxicity studies, liver histopathology revealed that the formulation MTX-TEF-HAp-NP was least hepatotoxic with less hepatocyte swelling and fibrous connective tissue proliferation while Folitrax-10 was found to be most hepatotoxic. Biochemical studies revealed that Folitrax-10 significantly (P < 0.05) increased the GOT (313.64 ± 16) and GPT level (334.46 ± 13) while insignificant (P > 0.05) change in GOT (263.68 ± 17) and GPT (229.38 ± 10) level was recorded with TEF-MTX-HAp-NP. CONCLUSIONS: We report that the subcutaneous delivery of TEF-MTX-HAp-NP was most effective as it successfully reduced the dosage by half for maximizing therapeutic efficacy and minimizing side effects. Graphical Abstract á .
Assuntos
Antirreumáticos/administração & dosagem , Artrite Experimental/tratamento farmacológico , Artrite Reumatoide/tratamento farmacológico , Crotonatos/administração & dosagem , Durapatita/química , Metotrexato/administração & dosagem , Nanopartículas/química , Toluidinas/administração & dosagem , Animais , Antirreumáticos/farmacocinética , Antirreumáticos/farmacologia , Artrite Experimental/patologia , Artrite Reumatoide/patologia , Crotonatos/farmacocinética , Crotonatos/farmacologia , Portadores de Fármacos , Combinação de Medicamentos , Composição de Medicamentos , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Feminino , Concentração de Íons de Hidrogênio , Hidroxibutiratos , Cinética , Metotrexato/farmacocinética , Metotrexato/farmacologia , Nitrilas , Estresse Oxidativo/efeitos dos fármacos , Tamanho da Partícula , Ratos , Ratos Wistar , Distribuição Tecidual , Toluidinas/farmacocinética , Toluidinas/farmacologiaRESUMO
BACKGROUND: Bendamustine HCl, an antineoplastic drug, has a very short life of about 40 minutes which necessitates administration of large doses which leads to increased side effects as well as costs. OBJECTIVE: The present work describes the fabrication, optimization, and evaluation of bioactive hydroxyapatite nanoparticles to achieve sustained delivery of bendamustine HCl. METHODS: Hydroxyapatite nanoparticles (NPs) were prepared by the wet chemical precipitation method by reacting a calcium and phosphate precursor and the reaction was optimized via Box-Behnken DOE. The drug was loaded on particles by physical adsorption. Various analytical studies were performed on the fabricated nanoparticles in addition to biodistribution studies to establish the physicochemical and biological characteristics of the designed formulation. RESULTS: pH of the reactant solution was found to have a more profound effect on the particle size and size distribution in comparison to reactant concentration. The particles were found to have a spherical morphology by SEM. Size of the blank and drug-loaded nanoparticles was found to be 130±20 nm by TEM. Energy Dispersive X-ray Spectroscopy (EDS) studies confirmed the presence of hydroxyapatite as the dominant phase while DSC studies indicated the presence of the drug in its amorphous form after its adsorption on NPs. Tissue distribution studies further suggested that the majority of drug concentration was released in blood rather than the other organs implying low organ toxicity. CONCLUSION: Bendamustine loaded hydroxyapatite nanoparticles were successfully optimized and fabricated. Favorable results were obtained in in vitro, in vivo, and analytical studies.
Assuntos
Antineoplásicos Alquilantes/farmacocinética , Cloridrato de Bendamustina/farmacocinética , Durapatita/farmacocinética , Nanopartículas/química , Animais , Antineoplásicos Alquilantes/síntese química , Antineoplásicos Alquilantes/química , Cloridrato de Bendamustina/síntese química , Cloridrato de Bendamustina/química , Composição de Medicamentos , Durapatita/química , Concentração de Íons de Hidrogênio , Masculino , Tamanho da Partícula , Ratos , Ratos Wistar , Propriedades de Superfície , Distribuição TecidualRESUMO
An insight into the complex cancer pathophysiology reveals that a dependable amelioration of the disease could only be envisaged with a multipronged treatment approach. It is highly evident that singular chemotherapeutic agents used in clinical practice have shown limitations like severe side effects, MDR and are often associated with poor QOL while combinations of drugs have yielded better therapeutic outcomes. The current hypothesis takes it a step forward wherein a chemotherapeutic agent is combined with a natural chemosensitizer, both loaded into a nanopotentiated particulate system, which would eventually deliver the drug cargo at the target site with certitude. The encapsulated natural bioactive would then favorably act on the tumor milieu through multiple portals and chemosensibilize the cells towards cytotoxic action of the synthetic drug moiety. This 2C (chemotherapeutic and chemosensitizer) approach along with nanosystem's attributes like high payload, prolonged action and diminished side effects would proffer a more dependable treatment modality. In conclusion, the proposed system would be a value addition to the currently available armamentarium of cancer treatment tools.
Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Sistemas de Liberação de Medicamentos/métodos , Quimioterapia Combinada/métodos , Modelos Biológicos , Nanopartículas/uso terapêutico , Neoplasias/tratamento farmacológico , Antineoplásicos Fitogênicos/química , Curcumina/uso terapêutico , Flavonoides/uso terapêutico , Fluoruracila , Humanos , Nanopartículas/química , Resveratrol , Estilbenos/uso terapêuticoRESUMO
The main objective of this study was to develop a microemulsion (ME) formulation for transdermal delivery of ondansetron for chemotherapy induced nausea and vomiting (CINV). For the formulation development oil was selected on the basis of drug solubility in it while the surfactants and co-surfactants (S(mix)) were screened on the basis of their capacity to solubilize the oil as well as their efficiency to provide the microemulsion area. The microemulsion existence ranges were defined through the construction of the pseudo-ternary phase diagram and various formulations were developed. Effect of surfactant and cosurfactant mass ratio (S(mix)) on the microemulsion formation and its permeation through excised rat skin was studied. A significant increase in permeability parameters such as steady-state flux (J(ss)), permeability coefficient (K(p)), and enhancement ratio (ER) was observed in ME. Formulation B4 which consisted of 0.5% (w/w) of ondansetron, 5% (w/w) of oleic acid, 30% (w/w) S(mix) (2:1, Tween 20 and PEG 400) and 64.5% (w/w) of distilled water showed the best permeability profile. The formulation B4 was subjected to various in vitro attributes and converted to microemulsion gel (OMG). In order to predict the efficacy, pharmacokinetic studies were performed and pharmacokinetic profile was compared with ondansetron conventional gel (OCG) and oral marketed syrup (ONDANZ). The absorption of ondansetron from OMG resulted in 6.03 fold increase in bioavailability as compared to oral conventional syrup and 9.66 times with reference to the OCG gel. The future perspective includes preclinical, toxicological and clinical studies for developing clinically viable formulation.
Assuntos
Administração Cutânea , Antieméticos/administração & dosagem , Antieméticos/farmacocinética , Náusea/tratamento farmacológico , Ondansetron/administração & dosagem , Ondansetron/farmacocinética , Vômito/tratamento farmacológico , Animais , Área Sob a Curva , Centrifugação , Química Farmacêutica , Relação Dose-Resposta a Droga , Estabilidade de Medicamentos , Emulsões , Feminino , Congelamento , Géis , Óleos de Plantas , Ratos , Ratos Wistar , Absorção Cutânea , Tensoativos , TermodinâmicaRESUMO
The singular aim of the proposed work is the development of a synergistic thermosensitive gel for vaginal application in subjects prone to recurrent vaginal candidiasis and other microbial infections. The dual loading of Itraconazole and tea tree oil in a single formulation seems promising as it would elaborate the microbial coverage. Despite being low solubility of Itraconazole in tea tree oil, a homogeneous, transparent and stable solution of both was created by co-solvency using chloroform. Complete removal of chloroform was authenticated by GC-MS and the oil solution was used in the development of nanoemulsion which was further translated into a gel bearing thermosensitive properties. In vitro analyses (MTT assay, viscosity measurement, mucoadhesion, ex vivo permeation, etc.) and in vivo studies (bioadhesion, irritation potential and fungal clearance kinetics in rat model) of final formulation were carried out to establish its potential for further clinical evaluation.
Assuntos
Candidíase Vulvovaginal/tratamento farmacológico , Géis/uso terapêutico , Teste de Materiais/métodos , Adesividade/efeitos dos fármacos , Animais , Antifúngicos/farmacologia , Morte Celular/efeitos dos fármacos , Sinergismo Farmacológico , Emulsões/química , Feminino , Géis/farmacologia , Células HeLa , Humanos , Itraconazol/farmacologia , Itraconazol/uso terapêutico , Itraconazol/toxicidade , Cinética , Muco/efeitos dos fármacos , Nanopartículas/química , Tamanho da Partícula , Ratos , Tensoativos/química , Óleo de Melaleuca/farmacologia , Óleo de Melaleuca/uso terapêutico , Óleo de Melaleuca/toxicidade , Temperatura , Temperatura de Transição , Viscosidade/efeitos dos fármacosRESUMO
Cancer treatment, owing to its myriad limitations, has often been a formidable challenge to both the practitioners as well as researchers. There has been a continued effort in designing newer and successful strategies to obtain optimal results. One such strategy includes the elucidation of a combinatorial approach of the conventional chemotherapy protocol with various mechanophysical methods. This opinion article discusses that how two thrust areas like targeting cancerous cells using a novel drug-delivery system and mechanophysical methods of killing them can be amalgamated into a complete new vector, which is driven with precision, specificity, accuracy, and better efficacy. This approach relies on devising a mechanophysical responsive vehicle, which could be added to other anticancer therapies. The new combined tool would then kill the cancer cells not just by releasing the chemotherapeutic drug at the desired site but also by killing individual cells through the purported mechanophysical stimuli. Summarily, the resultant vector generates an angle influenced by the direction of the mechanophysical vector, leading to a better therapeutic modality.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Portadores de Fármacos/uso terapêutico , Sistemas de Liberação de Medicamentos , Neoplasias/terapia , Técnicas de Ablação , Terapia Combinada , Humanos , Hipertermia Induzida , FotoquimioterapiaRESUMO
The recognition of periodontal diseases as amenable to local antibiotherapy has resulted in a paradigmatic shift in treatment modalities of dental afflictions. Moreover the presence of antimicrobial resistance, surfacing of untoward reactions owing to systemic consumption of antibiotics has further advocated the use of local delivery of physiologically active substances into the periodontal pocket. While antimicrobials polymerized into acrylic strips, incorporated into biodegradable collagen and hollow permeable cellulose acetate fibers, multiparticulate systems, bio-absorbable dental materials, biodegradable gels/ointments, injectables, mucoadhesive microcapsules and nanospheres will be more amenable for direct placement into the periodontal pockets the lozenges, buccoadhesive tablets, discs or gels could be effectively used to mitigate the overall gingival inflammation. Whilst effecting controlled local delivery of a few milligram of an antibacterial agent within the gingival crevicular fluid for a longer period of time, maintaining therapeutic concentrations such delivery devices will circumvent all adverse effects to non- oral sites. Since the pioneering efforts of Goodson and Lindhe in 1989, delivery at gingival and subgingival sites has witnessed a considerable progress. The interest in locally active systems is evident from the patents being filed and granted. The present article shall dwell in reviewing the recent approaches being proffered in the field. Patents as by Shefer, et al. US patent, 6589562 dealing with multicomponent biodegradable bioadhesive controlled release system for oral care products, Lee, et al. 2001, US patent 6193994, encompassing a locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof and method of treating periodontal disease as suggested by Basara in 2004via US patent 6830757, shall be the types of intellectual property reviewed and presented in the current manuscript.
Assuntos
Antibacterianos/administração & dosagem , Sistemas de Liberação de Medicamentos , Doenças Periodontais/tratamento farmacológico , Adesividade , Antibacterianos/efeitos adversos , Preparações de Ação Retardada , Líquido do Sulco Gengival/metabolismo , Humanos , Testes de Sensibilidade Microbiana , Patentes como Assunto , Doenças Periodontais/microbiologia , Bolsa Periodontal/tratamento farmacológico , Bolsa Periodontal/microbiologia , Estados UnidosRESUMO
P-glycoprotein (P-gp) is found to play a very significant role in intestinal and biliary transport of irinotecan and its active metabolite, SN-38. This makes P-gp inhibition a logical strategy for improving irinotecan's oral efficacy and reducing its toxicity. The objective of the present study was to identify the most suitable P-gp inhibitor, amongst various commonly used herbal components via in vitro screening; followed by determination of in vivo effects in rats. Caco-2 cell monolayers were used to investigate the influence of various components (quercetin, hesperitin, piperine, curcumin and naringenin) on the transport of irinotecan. The secretory transport (basolateral-to-apical) was significantly decreased by all components (p<0.05) except piperine. In the apical-to-basolateral transport, quercetin showed the highest absorptive permeability enhancement and P-gp interaction potential making it an appropriate candidate for further in vivo studies in female Wistar rats. Quercetin pre-treatment resulted in increased irinotecan C(max) and area under curve (AUC) with a concomitant decrease in t(max), plasma clearance and volume of distribution (p<0.05). The absolute bioavailability (F) of irinotecan control was 33%, which was increased to 43% (1.3 fold) by quercetin administration. The amounts of irinotecan and SN-38 eliminated in bile in control rats, is reduced to almost half when treated with quercetin. Our studies not only propose a safe approach for bioavailability enhancement and reducing toxicity of irinotecan by P-gp inhibition but in another way also reiterate the significance of elucidating herb-drug interactions for future insights.